1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Lung Infections – Pipeline Review, H1 2013

Lung Infections – Pipeline Review, H1 2013

  • February 2013
  • -
  • Global Markets Direct
  • -
  • 57 pages

Lung Infections – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Lung Infections - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Lung Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lung Infections. Lung Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Lung Infections.
- A review of the Lung Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Lung Infections pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Lung Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Lung Infections pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Lung Infections - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Lung Infections Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Lung Infections 7
Lung Infections Therapeutics under Development by Companies 9
Lung Infections Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Pre-Clinical Stage Products 14
Comparative Analysis 14
Lung Infections Therapeutics - Products under Development by Companies 15
Lung Infections Therapeutics - Products under Investigation by Universities/Institutes 16
Companies Involved in Lung Infections Therapeutics Development 17
Targeted Genetics Corporation 17
Bayer AG 18
Insmed Incorporated 19
PolyMedix, Inc. 20
ProtAffin Biotechnologie AG 21
Destiny Pharma Ltd. 22
Lung Infections - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
amikacin - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
ciprofloxacin - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
amikacin - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
amikacin - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
PA-401 - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
Anti-Pseudomonas aeruginosa Vaccine - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
BioPhage-PR - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
XF-70 - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
Lung Infections Therapeutics - Drug Profile Updates 40
Lung Infections Therapeutics - Discontinued Products 50
Lung Infections Therapeutics - Dormant Products 51
Lung Infections - Product Development Milestones 52
Featured News and Press Releases 52
Aug 02, 2012: Insmed Receives Second Composition Of Matter Patent For ARIKACE 52
Jun 27, 2012: Insmed Doses First Patient In TARGET-NTM Phase II Clinical Trial Of ARIKACE in Patients With Non-Tuberculous Mycobacteria Lung Disease 52
May 23, 2012: Insmed Begins Screening Patients For TARGET-NTM US Clinical Trial Of ARIKACE In Patients With Non-Tuberculous Mycobacterial Lung Disease 53
May 07, 2012: Insmed Announces Lifting Of Clinical Hold By FDA On ARIKACE In Cystic Fibrosis Patients With Pseudomonas Lung Infections 54
Sep 15, 2011: Nabriva Therapeutics Presents Extended Phase II Results For Pleuromutilin Antibiotic BC-3781 54
Appendix 56
Methodology 56
Coverage 56
Secondary Research 56
Primary Research 56
Expert Panel Validation 56
Contact Us 57
Disclaimer 57



List of Tables

Number of Products Under Development for Lung Infections, H1 2013 7
Products under Development for Lung Infections - Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 9
Number of Products under Investigation by Universities/Institutes, H1 2013 10
Comparative Analysis by Late Stage Development, H1 2013 11
Comparative Analysis by Mid Clinical Stage Development, H1 2013 12
Comparative Analysis by Early Clinical Stage Development, H1 2013 13
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 14
Products under Development by Companies, H1 2013 15
Products under Investigation by Universities/Institutes, H1 2013 16
Targeted Genetics Corporation, H1 2013 17
Bayer AG, H1 2013 18
Insmed Incorporated, H1 2013 19
PolyMedix, Inc., H1 2013 20
ProtAffin Biotechnologie AG, H1 2013 21
Destiny Pharma Ltd., H1 2013 22
Assessment by Monotherapy Products, H1 2013 23
Assessment by Stage and Route of Administration, H1 2013 25
Assessment by Stage and Molecule Type, H1 2013 27
Lung Infections Therapeutics - Drug Profile Updates 40
Lung Infections Therapeutics - Discontinued Products 50
Lung Infections Therapeutics - Dormant Products 51



List of Figures

Number of Products under Development for Lung Infections, H1 2013 7
Products under Development for Lung Infections - Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Products under Investigation by Universities/Institutes, H1 2013 10
Late Stage Products, H1 2013 11
Mid Clinical Stage Products, H1 2013 12
Early Clinical Stage Products, H1 2013 13
Pre-Clinical Stage Products, H1 2013 14
Assessment by Monotherapy Products, H1 2013 23
Assessment by Route of Administration, H1 2013 24
Assessment by Stage and Route of Administration, H1 2013 25
Assessment by Molecule Type, H1 2013 26
Assessment by Stage and Molecule Type, H1 2013 27

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.